Sareum Holdings PLC Drawdown of Equity Prepayment Facility (3826U)
23 November 2023 - 6:00PM
UK Regulatory
TIDMSAR
RNS Number : 3826U
Sareum Holdings PLC
23 November 2023
Sareum Holdings PLC
("Sareum" or the "Company")
Drawdown of Equity Prepayment Facility
Cambridge, UK, 23 November 2023 - Sareum Holdings plc (AIM:
SAR), a biotechnology company developing next generation kinase
inhibitors for autoimmune disease and cancer, announces that it has
drawn down on the GBP0.3 million Second Deposit in respect of the
Equity Prepayment Facility announced on 3 August 2023.
In accordance with the terms of the Equity Prepayment Facility,
the Company will issue 227,892 four year warrants over ordinary
shares of 1.25p each exercisable at a price of GBP0.829337 to
Riverfort.
Unless otherwise defined herein, all capitalised terms in this
announcement shall have the meanings assigned to them in the
Company's announcements of 3 August 2023.
For further information, please contact:
Sareum Holdings plc
Tim Mitchell, CEO 01223 497700
Lauren Williams, Head of Investor Relations ir@sareum.co.uk
Strand Hanson Limited (Nominated Adviser)
James Dance / James Bellman 020 7409 3494
Peel Hunt LLP (Joint Corporate Broker)
James Steel / Patrick Birkholm 020 7418 8900
Hybridan LLP (Joint Corporate Broker)
Claire Noyce
020 3764 2341
ICR Consilium (Financial PR)
Jessica Hodgson / Davide Salvi / Stella
Lempidaki 020 3709 5700
About Sareum
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology
company developing next generation kinase inhibitors for autoimmune
disease and cancer.
The Company is focused on developing next generation small
molecules which modify the activity of the JAK kinase family and
have best-in-class potential. Its lead candidate, SDC-1801,
simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential
treatment for a range of autoimmune diseases and has entered Phase
1a/b clinical development with an initial focus on psoriasis.
Sareum has an economic interest in SRA737, a clinical-stage Chk1
inhibitor which it originally developed in collaboration with
several Cancer Research UK-related organisations. SRA737 has shown
promising safety and efficacy in two Phase 1/2 clinical trials.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a
potential application for cancer immunotherapy.
Sareum Holdings plc is based in Cambridge, UK, and is listed on
the AIM market of the London Stock Exchange, trading under the
ticker SAR. For further information, please visit the Company's
website at www.sareum.com
- Ends -
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFZMZMNZLGFZM
(END) Dow Jones Newswires
November 23, 2023 02:00 ET (07:00 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From May 2024 to Jun 2024
Sareum (LSE:SAR)
Historical Stock Chart
From Jun 2023 to Jun 2024